TP-04 is under clinical development by Tarsus Pharmaceuticals and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TP-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TP-04 overview
TP-04 is under development for the treatment of Papulopustular Rosacea. It is administered by topical route as a gel. It acts by targeting parasite-specific GABA-Cl channels.
Tarsus Pharmaceuticals overview
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics. The company’s pipeline products include TP-03, TP-04 and TP-05. Its pipeline treats meibomian gland disease, rosacea disease, lyme disease and malaria. Tarsus Pharmaceuticals also carries out Xdemvy for the treatment of demodex blepharitis, an eyelid margin disease characterized by inflammation, redness and ocular irritation. The company has operations across the US. Tarsus Pharmaceuticals is headquartered in Irvine, California, the US.
For a complete picture of TP-04’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
